| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000008812 |
| Receipt No. | R000010359 |
| Official scientific title of the study | Efficacy and safety of tocilizumab mono-therapy in patients with large vessel vasculitis (LVV; giant cell arteritis or Takayasu arteritis) and polymyalgia rheumatica (PMR) |
| Date of disclosure of the study information | 2012/10/01 |
| Last modified on | 2018/08/09 (Ver. 8) |
| Basic information | ||
| Official scientific title of the study | Efficacy and safety of tocilizumab mono-therapy in patients with large vessel vasculitis (LVV; giant cell arteritis or Takayasu arteritis) and polymyalgia rheumatica (PMR) | |
| Title of the study (Brief title) | Treatment of LVV and PMR by tocilizumab mono-therapy | |
| Region |
|
|
| Condition | ||
| Condition | Rheumatoid arthritis | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To evaluate the efficacy and safety of tocilizumab monotherapy for LVV and PMR |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | |
| Assessment | |
| Primary outcomes | mprovement of major clinical signs and symptoms at week 12(fever,abnormal findings of temporal artery, myalgia, serum CRP, ESR, abnormal radiological findings of the affected vessels) |
| Key secondary outcomes | Improvement of major clinical signs at week 52, relapse rate and adverse events during 52 weeks |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Historical |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | tocilizumab monotherapy | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patients who fulfilled the 1990 ACR classification criteria for giant cell arteritis and Takayasu arteritis and the 2012 EULAR/ACR provisional classification criteria for PMR
1) Bloch DA, et al.: The ACR 1990 criteria for the classification of vasculitis. Patients and methods. Arthritis Rheum 1990; 33:1068-1073 2) Dasgupta B, et al.: 2012 Provisional classification criteria for polymyalgia rheumatica: a EULAR/ACR collaborative initiative. Arthritis Rheum 2012; 64: 943-954 |
|||
| Key exclusion criteria | 1) patients who are prohibited to use tocilizumab by the JCR guideline for proper tocilizumab use
2) patients who are thought to be inappropriate for the treatment with tocilizumab by their attending doctor |
|||
| Target sample size | 40 | |||
| Research contact person | |
| Name of lead principal investigator | Koichi Amano |
| Organization | Saitama Medical Center,
Saitama Medical University |
| Division name | Department of Rheumatology and Clinical Immunology |
| Address | 1981 Kamoda, Kawagoe, Saitama, 350-8550, Japan |
| TEL | 049-228-3859 |
| amanokoi@saitama-med.ac.jp | |
| Public contact | |
| Name of contact person | Ryota Sakai |
| Organization | Saitama Medical Center, Saitama Medical Universitity |
| Division name | Department of Rheumatology & Clinical Immunology |
| Address | 1981 Kamoda Kawagoe, Saitama 350-8550 |
| TEL | 0492283574 |
| Homepage URL | |
| r_sakai@saitama-med.ac.jp | |
| Sponsor | |
| Institute | Department of Rheumatology & Clinical Immunology
Saitama Medical Center, Saitama Medical Universitity |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Department of Rheumatology & Clinical Immunology
Saitama Medical Center, Saitama Medical Universitity |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Partially published |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010359 |